Bridge Biotherapeutics Announces China NMPA Clearance of IND for BBT-401, a Pellino-1 Inhibitor for UC

By In The News
December 26, 2019 in The Headlines

Recommended Posts

In The News

Posted December 26, 2019

- Share

Posted December 26, 2019

China NMPA cleared the IND application of BBT-401 submitted on September 25, 2019 The Phase I clinical study in China will be initiated in May 2020 SEONGNAM, South Korea, Dec. 26, 2019 /PRNewswire/ -- Bridge Biotherapeutics Inc. (KOSDAQ: 288330), a clinical stage biotech company...

View the full article

Link to comment

Share on other sites

Archived

This topic is now archived and is closed to further replies.

Go to topic listing

Most Contributions
1. In The News
  222597
2. Jaydee
  18130
3. deicer
  13660
4. Kip Powick
  12352
5. dagger
  9615
Tell a friend
Love The Airline Website? Tell a friend!
- Email
- Share
Forum Statistics
- Total Topics
  
  273k
- Total Posts
  
  566.6k

Sign In

Bridge Biotherapeutics Announces China NMPA Clearance of IND for BBT-401, a Pellino-1 Inhibitor for UC

Recommended Posts

In The News

Link to comment

Share on other sites

Archived

Most Contributions

Tell a friend

Forum Statistics

Browse

Activity

Support